FOSCARNET PRESCRIBING INFORMATION PDF

are concise point-of-care prescribing, dosing and administering information to Prior to the initial foscarnet infusion, establish diuresis by administering Prehydrate with mL NS or D5W before first infusion to decrease risk for nephrotoxicity. See prescribing information for dose adjustments for CrCl < Group: antiviral. Solution for injection, 24 mg/ml ml, ml [non-EDL]. General information. Foscarnet is a non-nucleoside pyrophosphate analogue given.

Author: Tygomi Shaktigis
Country: Namibia
Language: English (Spanish)
Genre: Spiritual
Published (Last): 20 February 2005
Pages: 249
PDF File Size: 20.10 Mb
ePub File Size: 6.83 Mb
ISBN: 782-9-89686-236-1
Downloads: 83562
Price: Free* [*Free Regsitration Required]
Uploader: Nataxe

Bicisate Foscarnet may decrease the excretion rate of Bicisate which could result in a higher serum level. Concomitant use may increase the risk for QT prolongation.

Amantadine Foscarnet may decrease the excretion rate of Amantadine which could result in a higher serum level. Moderate Abnormal renal function has been observed in clinical practice during the use of foscarnet in combination with ritonavir.

Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval. This is not necessary after the patient has been reduced to maintenance doses.

Cinnamaldehyde Foscarnet may decrease the excretion rate of Cinnamaldehyde which could result in a higher serum level. Almasilate Foscarnet may ptescribing the excretion rate of Niformation which could result in a higher serum level. Fosfomycin Foscarnet may decrease the excretion rate of Fosfomycin which could result in a higher serum level.

Romidepsin The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Romidepsin. Loperamide The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Loperamide.

Foscavir 24 mg/ml Solution for Infusion – Summary of Product Characteristics (SmPC) – (eMC)

Seizures, including cases of status epilepticus, have been reported with foscarnet therapy, and are associated with foscarnet-induced alterations in plasma minerals and electrolytes. Arsenic trioxide The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Arsenic trioxide.

  GRAMATICA COREANA PDF

Alprazolam Foscarnet may decrease the excretion rate of Alprazolam which could result in a higher serum level. Amisulpride The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Amisulpride.

Your doctor will probably check the level of calcium in your blood before you receive foscarnet injection and during treatment. Moderate Monitor for changes in serum creatinine and phosphorus if tenofovir is administered in combination with nephrotoxic agents, such as foscarnet.

In clinical trials, QT prolongation was reported in patients who received midostaurin as single-agent therapy or in combination with cytarabine and daunorubicin. Feprazone The risk or severity of nephrotoxicity can be increased when Feprazone is combined with Foscarnet. Genital discomfort and ulceration c. This site uses cookies.

Potential QT prolongation has been reported in limited case reports with metronidazole. Aminohippuric acid The excretion of Aminohippuric acid can be decreased when combined with Foscarnet. Tricyclic antidepressants share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, foscarnft in overdose or with higher-dose prescription therapy elevated serum concentrations.

Olopatadine The risk or severity of QTc prescirbing can be increased when Foscarnet is combined with Olopatadine. Sulfamethoxazole Foscarnet may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level. Therefore, patients must be carefully monitored for such changes and their potential sequelae.

Idebenone Foscarnet may decrease the excretion rate of Idebenone which could result in a higher serum level. Eperisone The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Eperisone.

  ASUS TUSI-M MANUAL PDF

Due to the sodium content of Foscavir micromoles 5. The dose must be reduced in patients with renal insufficiency according informatoon the creatinine clearance level as described in the table above.

PDR Search

For Indormation infections, see encephalitis. Dimenhydrinate The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Dimenhydrinate. Eliglustat The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Eliglustat. One fatality has been reported from severe hypocalcemia following this combination. Adverse effects Nephrotoxicity, hypomagnesaemia, hypocalcaemia, hypokalaemia, hypophosphataemia, hypercalcaemia accompanied by perioral tingling, numbness in the extremities, paraesthesiahyperphosphataemia, headache, nausea, vomiting, rash, convulsions though to be associated with hypocalcaemiagenital ulceration, and anaemia.

Although causality for TdP has not been flscarnet for flecainide, patients receiving concurrent drugs which have the potential for QT prolongation may have an increased risk of developing proarrhythmias.

Foscarnet Injection: MedlinePlus Drug Information

Electrocardiogram QT prolonged, ventricular arrhythmia, torsade de pointes. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as tacrolimus. Both QT prolongation and torsade de pointes TdP have been reported during postmarketing use of foscarnet. Voriconazole has also been associated with QT preescribing and rare cases of TdP.